

Supplemental Digital Content 4: Table Showing Crude Hazard Ratios for Covariate Effect on Rates of Loss to Follow-up and Death among Adults Initiating Antiretroviral Therapy in Mozambique during 2004–2013

		Original n	Rate/100PY	Loss to Follow-up HR (95% CI)	p	Rate/100PY	Death HR (95% CI)	p
Year of ART Initiation	2004	1,784	11.0	1.00	—	2.9	1.00	—
	2005	4,694	10.2	0.94 (0.73-1.20)	0.611	2.7	0.82 (0.47-1.46)	0.508
	2006	12,634	12.1	1.12 (0.95-1.32)	0.177	3.3	0.96 (0.43-2.11)	0.912
	2007	25,616	13.6	1.28 (1.09-1.50)	0.003	3.1	0.88 (0.38-2.01)	0.754
	2008	26,704	15.9	1.47 (1.24-1.74)	<0.001	3.2	0.83 (0.35-1.95)	0.663
	2009	31,129	15.9	1.42 (1.09-1.85)	0.010	3.1	0.73 (0.30-1.77)	0.483
	2010	37,449	18.7	1.58 (1.13-2.20)	0.007	2.9	0.60 (0.25-1.45)	0.255
	2011	41,991	25.7	1.91 (1.32-2.76)	0.001	2.9	0.48 (0.20-1.18)	0.110
	2012	58,892	39.5	2.35 (1.56-3.54)	<0.001	3.1	0.38 (0.15-0.93)	0.034
	2013	65,442	77.7	2.79 (1.71-4.54)	<0.001	4.6	0.30 (0.12-0.73)	0.008
Age Category	15-<20	10,485	45.7	1.00	—	4.1	1.00	—
	20-<25	38,533	31.8	0.77 (0.73-0.82)	<0.001	3.5	0.95 (0.85-1.07)	0.417
	25-<30	60,910	24.5	0.63 (0.59-0.68)	<0.001	3.1	0.91 (0.79-1.04)	0.173
	30-<40	106,882	19.8	0.53 (0.49-0.58)	<0.001	2.8	0.88 (0.76-1.02)	0.082
	>=40	89,525	16.7	0.46 (0.42-0.50)	<0.001	4.1	1.05 (0.90-1.23)	0.429
Sex	Non-Pregnant Females	175,258	18.6	1.00	—	2.4	1.00	—
	Males	100,333	24.5	1.27 (1.22-1.31)	<0.001	4.9	1.94 (1.83-2.06)	<0.001
	Pregnant Females	30,744	31.8	1.42 (1.27-1.57)	<0.001	1.1	0.37 (0.32-0.44)	<0.001
Marital Status	married	138,559	20.6	1.00	—	3.0	1.00	—
	single	99,540	24.0	1.15 (1.08-1.22)	<0.001	3.3	1.08 (1.02-1.14)	0.012
	widowed/divorced	20,975	15.4	0.81 (0.77-0.85)	<0.001	2.5	0.90 (0.82-0.99)	0.031
No of Biological Children	0 children	34,165	22.2	1.00	—	3.8	1.00	—
	1-2 children	99,969	23.9	0.98 (0.92-1.04)	0.564	3.0	0.70 (0.62-0.79)	<0.001
	>=3 children	111,210	18.9	0.81 (0.76-0.86)	<0.001	2.9	0.70 (0.62-0.79)	<0.001
Education level	none	28,606	22.4	1.00	—	3.3	1.00	—
	primary	143,102	21.1	0.95 (0.89-1.01)	0.094	3.1	0.94 (0.85-1.04)	0.249
	secondary	55,664	21.3	0.94 (0.86-1.03)	0.195	3.0	0.89 (0.78-1.02)	0.090
	university	3,454	22.3	1.00 (0.84-1.19)	0.978	3.0	0.91 (0.64-1.29)	0.592
Employment	employed	64,340	19.2	1.00	—	3.4	1.00	—
	Unemployed	170,683	22.1	1.11 (1.05-1.18)	<0.001	3.0	0.86 (0.79-0.93)	0.001
	student	10,945	24.1	1.20 (1.14-1.26)	<0.001	2.7	0.76 (0.67-0.86)	<0.001
Referral Source	VCT	121,865	18.4	1.00	—	3.0	1.00	—
	PMTCT/EID	37,098	30.5	1.39 (1.25-1.54)	<0.001	1.2	0.32 (0.26-0.39)	<0.001
	TB clinic	7,132	29.0	1.43 (1.26-1.63)	<0.001	4.4	1.31 (1.08-1.58)	<0.001
	HC referral	121,034	22.6	1.16 (1.05-1.28)	0.004	3.6	1.14 (0.96-1.36)	0.133
	other	19,061	19.4	1.02 (0.93-1.11)	0.705	3.1	1.00 (0.73-1.36)	0.992
WHO Stage	I	76,685	23.1	1.00	—	1.5	1.00	—
	II	52,260	18.8	0.90 (0.84-0.96)	0.002	2.0	1.51 (1.39-1.63)	<0.001
	III	82,044	20.4	1.02 (0.93-1.12)	0.668	3.5	2.78 (2.51-3.08)	<0.001
	IV	21,372	26.3	1.31 (1.16-1.47)	<0.001	8.2	6.58 (5.80-7.46)	<0.001
Weight Categories	<45 kg	33,333	28.3	1.00	—	6.5	1.00	—
	45-60 kg	120,535	21.3	0.77 (0.74-0.80)	<0.001	3.0	0.47 (0.44-0.50)	<0.001
	>60 kg	52,667	17.8	0.65 (0.60-0.70)	<0.001	1.7	0.27 (0.24-0.29)	<0.001
CD4 Count Category	<50	28,226	23.9	1.00	—	6.2	1.00	—
	50-200	86,194	19.8	0.84 (0.81-0.87)	<0.001	3.1	0.51 (0.48-0.54)	<0.001
	201-350	71,741	20.4	0.82 (0.77-0.87)	<0.001	1.9	0.30 (0.27-0.32)	<0.001
	351-500	12,862	26.8	0.99 (0.92-1.07)	0.833	2.4	0.33 (0.29-0.38)	<0.001
	>500	9,660	32.0	1.11 (1.03-1.20)	0.006	2.7	0.35 (0.30-0.40)	<0.001
CASG patient	No	299,569	22.2	1.00	—	3.2	1.00	—
	Yes	6,766	2.7	0.69 (0.49-0.96)	0.030	0.4	0.90 (0.71-1.14)	0.399
CASG site	No	136,269	21.3	1.00	—	3.0	1.00	—
	Yes	170,066	21.4	1.02 (0.86-1.22)	0.811	3.2	1.05 (0.80-1.39)	0.717
Rate of Enrollment	<13 patients/month	61,267	20.1	1.00	—	4.2	1.00	—
	13-<24 patients/month	61,266	20.4	0.98 (0.86-1.12)	0.803	3.5	0.78 (0.64-0.94)	0.013
	24-<39 patients/month	61,267	21.8	1.06 (0.92-1.22)	0.430	2.5	0.57 (0.45-0.70)	<0.001
	39-<60 patients/month	61,268	23.2	1.04 (0.85-1.27)	0.694	2.7	0.54 (0.37-0.79)	0.002
	>=60 patients/month	61,267	21.5	0.93 (0.76-1.15)	0.507	2.3	0.46 (0.34-0.61)	<0.001
Site Size	1st quintile	5,820	29.7	1.00	—	7.7	1.00	—
	2nd quintile	18,384	27.2	0.98 (0.82-1.17)	0.817	4.8	0.66 (0.49-0.88)	0.006
	3rd quintile	38,393	24.1	0.87 (0.71-1.07)	0.194	4.5	0.62 (0.45-0.85)	0.003
	4th quintile	68,836	21.0	0.81 (0.65-1.01)	0.063	3.7	0.55 (0.39-0.76)	<0.001
	5th quintile	174,902	20.2	0.77 (0.63-0.96)	0.019	2.4	0.35 (0.25-0.50)	<0.001
Back-Bone	Zidovudine	166,840	28.8	1.00	—	2.5	1.00	—
	Stavudine	113,820	15.8	0.75 (0.65-0.86)	<0.001	3.4	2.24 (1.95-2.57)	<0.001
	Tenofovir	16,104	46.3	1.22 (0.96-1.56)	0.111	3.8	1.13 (0.60-2.12)	0.705
	Other	2,030	27.3	1.10 (0.96-1.27)	0.182	2.3	1.14 (0.77-1.68)	0.527
Third Drug	Nevirapine	248,958	20.2	1.00	—	2.9	1.00	—
	Efavirenz	42,903	32.6	1.35 (1.27-1.44)	<0.001	5.1	1.44 (1.22-1.70)	<0.001
	Protease Inhibitor	4,118	23.0	1.20 (0.99-1.45)	0.067	2.3	0.87 (0.71-1.08)	0.201
	Other	2,815	26.2	1.25 (1.09-1.43)	0.001	2.7	0.90 (0.54-1.50)	0.691

Abbreviations: PY, person-years; CI, confidence intervals; AHR, adjusted hazard ratio; WHO, World Health Organization; CASG, community antiretroviral therapy support group; VCT, voluntary counselling and testing; PMTCT/EID, prevention of mother-to-child transmission/early infant diagnosis; TB, tuberculosis; HC, health center.